Business Wire

Dahua Technology to Launch Three-in-One Camera Solution (TiOC)

17.8.2020 12:30:00 EEST | Business Wire | Press release

Share

Traditional security systems are having problems catching up with increasingly demanding scenarios: too much false alarms triggered by non-target objects; can only rely on video playback for confirmation after events; difficult evidence retrieval with uncolored images at night; extra cost and complicated installation for a relatively comprehensive system, etc.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200817005232/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Photo: Business Wire)

To address these issues, Dahua Technology (SZSE: 002236) launches its innovative and powerful Three-in-One Camera solution (TiOC), presenting the following features.

Accurate Alarm. False alarm is always a headache for users. With AI-powered perimeter protection and SMD Plus, the Dahua TiOC offers accurate alarm function by precisely targeting people and vehicles with an accuracy rate above 98%, filtering out non-target objects like pets, leaves, etc., considerably improving the efficiency of TiOC.

Active Deterrence & Real-time Alarm. The TiOC can respond during the event with Active Deterrence and Real-time Alarm functions. Active deterrence is more effective with red and blue light, which is eye-catching and also visible in dense fog and heavy rain. An enhanced speaker delivers up to 110 dB, featuring a wailing siren or a recorded voice. The TiOC also provides real-time alarm notifications, allowing users to respond in time.

Full-color. Enough reliable information is key during evidence retrieval. With industry-leading Full-color technology, the Dahua TiOC delivers color images day and night, largely enhancing the ability to identify suspects.

Three-in-One. TiOC integrates 24/7 full-color monitoring, active deterrence and AI into one smart, innovative solution, greatly saving time and cost for distributors and installers.

Application Scenarios

TiOC is suitable for private places that need to maintain orderliness and warn off intruders, such as villas, shops, warehouses, etc. TiOC can accurately identify real targets, effectively warn them off, and notify the user in real-time. The full-color image provides more useful human/vehicle evidence for future analysis.

TiOC is also ideal for outdoor scenarios like fire lanes, which need to be always free of vehicles. Give it a try, and TiOC will work like a responsible guardian, effectively maintaining emergency lanes clear.

Dahua TiOC Solution comprises WizSense IP cameras, HDCVI 6.0 cameras & XVRs, and upcoming PTZ cameras, and is applicable to villas, shops, warehouses, fire lanes, and places alike. With its mission of “Enabling a safer society and smarter living”, Dahua Technology will continue to focus on “Innovation, Quality and Service” to serve its partners and customers around the world.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Vivid Gu,
Gu_Jun1@dahuatech.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release

2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye